Inhibition of Orai Channel Function Regulates Mas-Related G Protein-Coupled Receptor-Mediated Responses in Mast Cells

Shaswati Chaki1, Ibrahim Alkanfari1,2, Saptarshi Roy1, Aetas Amponnawarat1,3, Yvonne Hui4, Carole A. Oskeritzian4 and Hydar Ali1*

1 Department of Basic and Translational Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, United States, 2 Faculty of Dentistry, King AbdulAziz University, Jeddah, Saudi Arabia, 3 Department of Family and Community Dentistry, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand, 4 Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States

Mast cells (MCs) are tissue resident immune cells that play important roles in the pathogenesis of allergic disorders. These responses are mediated via the cross-linking of cell surface high affinity IgE receptor (FccRI) by antigen resulting in calcium (Ca\textsuperscript{2+}) mobilization, followed by degranulation and release of proinflammatory mediators. In addition to FccRI, cutaneous MCs express Mas-related G protein-coupled receptor X2 (MRGPRX2; mouse ortholog MrgprB2). Activation of MRGPRX2/B2 by the neuropeptide substance P (SP) is implicated in neurogenic inflammation, chronic urticaria, mastocytosis and atopic dermatitis. Although Ca\textsuperscript{2+} entry is required for MRGPRX2/B2-mediated MC responses, the possibility that calcium release-activated calcium (CRAC/Orai) channels participate in these responses has not been tested. Lentiviral shRNA-mediated silencing of Orai1, Orai2 or Orai3 in a human MC line (LAD2 cells) resulted in partial inhibition of SP-induced Ca\textsuperscript{2+} mobilization, degranulation and cytokine/chemokine generation (TNF-\textalpha, IL-8, and CCL-3). Synta66, which blocks homo and hetero-dimerization of Orai channels, caused a more robust inhibition of SP-induced responses than knockdown of individual Orai channels, and also inhibited SP-induced Ca\textsuperscript{2+} mobilization and degranulation in primary human skin MCs and mouse peritoneal MCs. Furthermore, Synta66 attenuated both SP-induced cutaneous vascular permeability and leukocyte recruitment in mouse peritoneum. These findings suggest that Orai channels could provide a novel approach for the modulation of SP-induced MC/MRGPRX2-mediated disorders.

Keywords: Calcium release-activated calcium (CRAC), Orai, Mast cells, Mas-related G protein-coupled receptor X2 (MRGPRX2), Mas-related G protein-coupled receptor B2 (MrgprB2), Substance P
INTRODUCTION

Mast cells (MCs) are tissue resident immune cells best known for their roles in anaphylaxis and atopic disorders, which result from FccRI/IgE-mediated histamine release and the generation of lipid mediators and cytokines (1). It is well documented that the release of calcium (Ca\(^{2+}\)) from intracellular stores and its subsequent influx through store-operated calcium (SOC) channels are required for IgE-mediated release of newly synthesized mediators (2). Human and murine MCs express the endoplasmic reticulum (ER)-resident protein stromal interaction molecule-1 and -2 (STIM-1/2) that sense the depletion of intracellular Ca\(^{2+}\), resulting in the activation of calcium release-activated calcium (CRAC) channels such as CRACM1, CRACM2 and CRACM3 (also known as Orai1, Orai2 and Orai3) (3–6). Utilization of gene silencing and pharmacological approaches has demonstrated that Orai channels contribute to IgE-mediated degranulation in human lung MCs in vitro and bronchoconstriction ex vivo (6–8).

While all MCs are characterized by the expression of cell surface FceRI, cutaneous MCs highly expresses a newly identified G protein-coupled receptor (GPCR) known as Mas-related GPCR-X2 (MRGPRX2, mouse counterpart MrgprB2) (9). Activation of this receptor by an increasing list of cationic ligands contributes to host defense, pseudoallergy and a number of chronic inflammatory diseases (9–11). Substance P (SP)-mediated activation of human skin MCs via MRGPRX2 is implicated in the pathogenesis of chronic urticaria and mastocytosis (12, 13). Moreover, activation of murine MCs by SP via MrgprB2 contributes to experimental neurogenic inflammation, pain, and atopic dermatitis (14, 15). Although both anti-IgE and SP cause intracellular increase in Ca\(^{2+}\) concentration, the kinetics of Ca\(^{2+}\) mobilization varies for different stimuli. Stimulation of human peripheral blood-derived cultured MCs (PBMCs) with anti-IgE causes more sustained Ca\(^{2+}\) mobilization compared to SP. This is correlated with IgE-dependent progressive degranulation with larger granule size while SP stimulation results in faster degranulation with smaller granule size (16). However, the mechanism via which SP activates MRGPRX2 to cause Ca\(^{2+}\) mobilization and mediator release is unknown.

The purpose of this study was to determine if Orai channels contribute to SP-induced signaling and mediator release in human and murine MCs in vitro and MrgprB2-mediated inflammation in vivo. We utilized complementary approaches, namely, shRNA-mediated knockdown of Orai1, Orai2 and Orai3 in human MCs line, LAD2 and an Orai inhibitor, Synta66, in human skin-derived MCs and mouse peritoneal MCs for in vitro studies. We also tested the effects of Synta66 on SP-induced cutaneous vascular permeability and leukocyte recruitment in mouse peritoneum. This study provides novel insights on the role of Orai channels on MC activation by SP with potential implications for modulating MRGPRX2-mediated disorders.

MATERIALS AND METHODS

Reagents

All cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA); recombinant human stem cell factor (rhSCF), mouse interleukin-3 (mIL-3), and mouse stem cell factor (mSCF) were from PeproTech (Rocky Hill, NJ, USA); p-nitrophenyl-N-acetyl-β-D-glucosamine (PNG) was from Sigma-Aldrich (St. Louis, MO, USA) and Fura-2 acetoxyethyl ester was from Abcam (Cambridge, MA, USA). Substance P (SP) was from AnaSpec (Fremont, CA, USA). Phcoerythrin-conjugated anti-MRGPRX2, FITC-conjugated anti-LAMP-1 and all other flow cytometry antibodies were from Biolegend (San Diego, CA, USA). Rabbit anti-Orai1, Orai2 and Orai3 antibodies from Alomone lab (Rockville, MD, USA), anti-ERK1/2, anti-phospho-ERK1/2 (Thr-202/Tyr-204), anti-anti-phospho-Akt (Ser-473), anti-Akt, β-Actin and goat anti-rabbit IgG-HRP were obtained from Cell Signaling Technology (Danvers, MA, USA). SuperSignal West Pico Maximum Sensitivity Substrate was from Thermo Scientific (Rockford, IL, USA). Synta66 (3-fluoro-pyridine-4-carboxylic acid, 2,5-dimethoxy-biphenyl-4-yl)-amide was purchased from Calbiochem (San Diego, CA, USA). ELISA kits for mouse TNF-α, and human TNF-α, IL-8, CCL-3 were obtained from R&D system (Minneapolis, MN, USA). BCA Protein Assay Kit was obtained from Pierce Biotechnology (Rockford, IL, USA).

Mice

C57BL/6 (WT) mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). MrgprB2−/− mice were generated via CRISPR/Cas9 by CRISPR core of University of Pennsylvania (17). All mice were housed under specific pathogen-free conditions on autoclaved hardwood bedding. Both male and female mice (8–10 weeks old) were used for experiments. All experiments were approved by the Institutional Animal Care and Use Committee at University of Pennsylvania.

Cell Line Cultures

The human MC line LAD2 was provided by Dr. A. Kirshenbaum and Dr. D. Metcalfe (Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA) and was maintained in complete StemPro-34 medium supplemented with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 µg/ml), and rhSCF (100 ng/ml). Hemidepletion was performed weekly with media containing rhSCF (18).

Human Skin-Derived Primary Mast Cell Isolation and Culture

Human skin surgical sample was collected from the Cooperative Human Tissue Network of the National Cancer Institute, as

Abbreviations: CRAC, calcium release-activated calcium; FITC, fluorescein isothiocyanate; GPCR, G Protein-coupled receptor; IL-8, interleukin-8; TNF-α, Tumor Necrosis Factor-alpha; LAMP-1, lysosomal-associated membrane protein-1; MCs, mast cells; MFI, mean fluorescent intensity; MrgprB2, Mas-related G protein-coupled receptor B2; MRGPRX2, Mas-related G protein-coupled receptor X2; PE, phcoerythrin; PMCs, peritoneal mast cells; STIM-1, stromal interaction molecule-1; SOC, store-operated calcium; SP, substance P; WT, wild-type.
approved by the Internal Review Board at the University of South Carolina. Skin MCs were harvested and cultured as previously described (18, 19). Briefly, subcutaneous fat was removed by blunt dissection, and residual tissue was cut into 1 to 2 mm fragments and digested with type 2 collagenase (1.5 mg/ml), hyaluronidase (0.7 mg/ml), and DNase I (0.3 mg/ml) in Hank’s Balanced Salt Solution (HBSS) for 2 h at 37°C. The dispersed cells were collected by filtering through a 70-µm cell strainer and resuspended in HBSS containing 1% fetal calf serum (FCS) and 10 mM HEPES to stop the reaction. Cells were resuspended in HBSS and layered over 75% Percoll in a HBSS cushion and centrifuged at 800 g at room temperature for 20 min. Nucleated cells were collected from the buffer/Percoll interface. Percoll gradient-enriched cells were resuspended at a concentration of 1 × 10⁶ cells/ml in serum-free X-VIVO 15 medium containing 10% FCS and 10 mM HEPES, pH 7.2. The cells were cultured in ~20 g as described previously (20). Briefly, the peritoneal cavity was lavaged with 10 ml sterile cold HBSS supplemented with 3% FCS and 10 mM HEPES to stop the reaction. Cells were resuspended in HBSS and layered over 75% Percoll in a HBSS cushion and centrifuged at 800 g at room temperature for 20 min. Nucleated cells were collected from the buffer/Percoll interface. Percoll gradient-enriched cells were resuspended at a concentration of 1 × 10⁶ cells/ml in serum-free X-VIVO 15 medium containing 100 ng/ml rhSCF. MCs were used after 6–10 weeks of culture, when purity was nearly 100%, as confirmed with toluidine blue staining.

Isolation of Mouse Peritoneal MCs

Mouse peritoneal cells were isolated by intraperitoneal lavage from 8 to 10 weeks old C57BL/6 and MrgrpB2−/− mice weighing ~20 g as described previously (20). Briefly, the peritoneal cavity was lavaged with 10 ml sterile cold HBSS supplemented with 3% FCS and 10 mM HEPES, pH 7.2. The cells were cultured in Roswell Park Memorial Institute (RPMI 1640) medium supplemented with 10% FCS, murine IL-3 (10 ng/ml), and murine SCF (30 ng/ml). After 48 h, non-adherent cells were removed, and adherent cells were cultured in fresh medium for an additional 4–6 weeks. Suspension cells were used for experiments as peritoneal MCs (PMCs).

Generation and Purification of Scramble shRNA, Orai1 shRNA, Orai2 shRNA and Orai3 shRNA and Knockdown in LAD2 Cells Using Lentiviral Transduction

To inhibit Orai1, Orai2, and Orai3 protein expression in human MCs, lentiviral shRNA-mediated knockdown was performed in LAD2 cells. Orai1, Orai2, and Orai3 targeted Mission shRNA lentiviral plasmids were purchased from Sigma-Aldrich. The clones that gave highest knockdown efficacy for Orai1 (TRCN00000413611), Orai2 (TRCN0000166201), and Orai3 (TRCN0000165405) were used for the study. A nontargeted scramble vector (SHC002) was used as a control. Nontargeted control or respective Orai knockdown plasmids were packaged into virus particle using HEK293T cells. Targeted shRNA plasmid (4.5 µg) along with helper plasmid pCMV- VSV-G (Addgene# 8454, 0.57 µg) and pCMV-dR8.2 (Addgene# 8455, 4.5 µg) were transfected in HEK293T cells (6 × 10⁶ cells/transfection) in T75 flask. After 72 h, viral particles were harvested, filtered through 0.45 µm filter and concentrated using Lentivirus™ concentrator (Takara Bio Inc, Japan). Cell transduction was performed by mixing 1.5 ml of concentrated virus particles with 3.5 ml of LAD2 (10 × 10⁵ cells). After 8 h incubation in 37°C and 5% CO₂, medium was changed to complete StemPro34 media and antibiotic puromycin (2 µg/ml; Sigma) was added after 16 h (21). Western blotting was performed to confirm knockdown and experiments were performed 4 days after initiation of puromycin selection.

Degranulation Measured by β-Hexosaminidase Release Assay

The degranulation was measured by β-hexosaminidase release as described previously (21). Briefly, LAD2 cells (1 × 10⁶), human skin-derived MCs (5 × 10⁶), and PMCs (1 × 10⁶) were seeded into a 96-well, white, clear-bottom cell culture plate in HEPES buffer containing 0.1% bovine serum albumin (BSA) and stimulated with differing concentrations of SP for 30 min at 37°C. Cells without treatment were designated as control. To determine the total β-hexosaminidase content, unstimulated cells were lysed in 50 µl of 0.1% Triton X-100. Aliquots (20 µl) of supernatants or cell lysates were incubated with 20 µl of 1 mM p-nitrophenyl-N-acetyl-β-D-glucosamine (PNGA) for 1.15 h at 37°C. The reaction was stopped by adding 250 µl of stop solution (0.1 M Na₂CO₃/0.1 M NaHCO₃). For assays using CRAC inhibitor (Synta66), cells were incubated for 5 min with the suitable dose of inhibitor prior to agonist stimulations. The absorbance was measured with a microplate reader at a wavelength of 405 nm using Versamax microplate spectrophotometer (Molecular Devices, San Jose, CA, USA). Data was represented as percent degranulation by dividing the β-hexosaminidase release in sample with total β-hexosaminidase release.

Degranulation Measured by the Surface Expression of Lysosomal-Associated Membrane Protein 1 (LAMP-1)

Degranulation was also assessed by flow cytometric measurement of the surface expression of LAMP-1 (20). Murine PMCs (3 × 10⁵) were stimulated with SP (100 µM) for 10 min in HEPES buffer containing 0.1% BSA, washed and exposed to FITC-conjugated anti-LAMP-1 antibody in FACS buffer (PBS containing 2% FCS and 0.02% sodium azide) for 30 min on ice in dark. For experiments involving inhibitors, PMCs were incubated with Synta66 (10 µM) for 5 min prior to SP stimulation. Cell surface expression of LAMP-1 was measured by flow cytometry using a BD LSR II flow cytometer (San Jose, CA) and analyzed with the FlowJo software version 10.7.2 (Tree Star Inc., Ashland, OR). The adjusted mean fluorescent intensity (MFI) was calculated as a ratio of the MFI of sample to the MFI of isotype control.

Calcium Mobilization

LAD2 (0.3 × 10⁶ cells) cells were loaded with 1 µM Fura-2 acetoxymethyl ester in Ca²⁺-free HEPES-buffered saline containing 0.1% BSA for 30 min in the dark at 37°C, followed by de-esterification for additional 15 min at room temperature. Cells were washed, resuspended in Ca²⁺-free buffer and Ca²⁺ mobilization was measured for 25 min with addition of SP at 100 s and reintroduction of Ca²⁺ at 400 s. For assay with inhibitor, cells were loaded with Fura-2 acetoxymethyl ester (Fura-2AM) and incubated with 10 µM of Synta66 for 30 min in Ca²⁺-free buffer prior to ligand stimulation. Calcium signals
was determined using a Hitachi F-2700 Fluorescence Spectrophotometer with dual excitation wavelength of 340 and 380 nm, and an emission wavelength of 510 nm at every 2 s (22).

For the assay with human skin MCs, cells (0.2×10⁶) were loaded with Fura-2 acetoxymethyl ester similarly in presence and absence of Synta66, and Ca²⁺ mobilization was measured in Varioskan LUX Multimode Microplate Reader (ThermoScientific, Waltham, MA, USA).

**Western Blotting**

Western blotting was performed as described previously (17). Briefly, control and Orai shRNA transduced LAD2 cells (1×10⁶) were lysed in radioimmunoprecipitation assay buffer (1× RIPA) with protease inhibitor cocktail, and the protein concentration was measured by the BCA protein assay. Twenty five micrograms of protein samples were applied to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to PVDF membrane. After brief blocking (5% skim milk, 1 h), blots were incubated with antibodies against Orai1 (1:500), Orai2 (1:500), Orai3 (1:500) and β-Actin (1:1,000) at 4°C overnight. Blots were incubation with specific horseradish peroxidase (HRP)-conjugated secondary antibodies for another hour, followed by incubation with an HRP substrate for ECL and image captured on iBRIGHT 1500 (ThermoFisher, Waltham, MA, USA). Signal quantitation was carried out after normalization to β-Actin loading controls, as indicated. For the assay with Orai inhibitor, LAD2 cells (2×10⁶) were preincubated with Synta66 (10 µM) for 30 min, stimulated with SP (1 µM) for different time intervals (0, 5, 15 and 30 min) and cell lysates were prepared. Protein samples were run in SDS-PAGE, incubated with anti-phospho-pERK1/2 (1:2,000), anti-phospho-Akt (1:1,000), anti-ERK1/2 (1:2,000), and anti-Akt (1:1,000) antibodies and processed similarly.

**ELISA (Enzyme-Linked Immunosorbert Assay)**

ELISAs were performed according to the manufacturer’s protocol (DuoSet ELISA kits, R&D systems) to quantify the release of murine TNF-α and human TNF-α, IL-8 and CCL-3. Briefly, LAD2 cells were washed once in serum-free Stem-Pro™-34 medium, suspended in complete medium and seeded in 24-well sterile plate (0.3×10⁶ cells/well) with appropriate concentration of agonist stimulation for 24 h. For experiments involving Synta66, cells were preincubated with inhibitor for 30 min prior to agonist stimulation. After 24 h, cells were centrifuged, and supernatants were collected to measure cytokines by ELISA. The expression of mTNF-α was measured in serum samples from mice untreated or treated with Synta66 and SP.

**Murine Evans Blue Dye Extravasation Model**

Evans blue extravasation studies were performed on male and female C57BL/6 mice (8–10 weeks of age and weighing 20–25 g). Mice were anesthetized using Ketamine : Xylazine and intraperitoneally (i.p) injected with Synta66 (10 mg/kg in 50 µl DMSO) following intravenous (i.v.) injection with 0.1 ml of 1% Evans blue in saline. After 1 h, intradermal injection of SP (50 µM in 20 µl saline) was performed into the one ear, while vehicle was injected in other side. After 30 min, mice were euthanized; ear tissues were harvested, weighed, immersed in 500 µl of formamide and incubating overnight at 56°C. Each tissue solution was centrifuged at 10,000 rpm for 10 min; Evans blue dye extravasation was determined by collecting 200 µl of the supernatant and the OD values were measured at 650 nm using Versamax microplate spectrophotometer (20).

**In Vivo Murine Peritonitis Model**

In short, 8–10 weeks old C57BL/6 mice (male and female) were intraperitoneally (i.p) injected with 50 µl of Synta66 (10 mg/kg in DMSO) or vehicle. After 1 h, peritonitis was induced by intraperitoneal injection of SP (50 µl of 200 µM SP in saline) or vehicle. Three hours later, all mice were euthanized and peritoneal exudate was collected by flushing the peritoneal cavity with 10 ml of sterile cold 1× PBS and centrifuged at 400×g for 10 min at 4°C. Pellet-containing cells were processed for flow cytometric analysis and serum prepared from blood collected by cardiac puncture for cytokine measurement by ELISA (23, 24).

**Flow Cytometry Assay**

To quantify the leukocyte recruitment, we performed flow cytometry as described previously (15). Following induction of peritonitis by SP injection, peritoneal lavage was collected and cells were washed with FACS buffer. Peritoneal cells were treated with CD16/32 Fc block (clone93, cat#101320) for 15 min followed by anti-CD45-FITC (clone 30-F11; cat #103108), CD11b-PerCP-Cy5.5 (clone M1/70, cat#101227), and Ly6G-BV421 (clone IAB, cat#127628) for 45 min to stain neutrophils. Live versus Dead cells were stained using Zombie Yellow™ Fixable viability dye (Biolegend, CA). The data were acquired with BD LSR II flow cytometer (San Jose, CA) and analyzed by FlowJo software version 10.7.2 (Tree Star Inc., Ashland, OR). Neutrophils were gated as CD45⁺CD11b⁺Ly6G⁺ live cells.

**Statistical Analysis**

Statistical analyses were performed using GraphPad PRISM software version 9.0.1 (San Diego, CSA). Results were expressed as mean ± standard error of the mean (SEM) values derived from at least three independent experiments. Differences between groups were analyzed by analysis of variance (ANOVA) following by Dunnett’s, Sidak’s and Tukey’s multiple comparisons tests. A p-value less than or equal to 0.05 was considered to be significant.

**RESULTS**

**Knockdown of Orai1/2/3 Partially Inhibit SP/MRGPRX2-Mediated Ca²⁺ Influx and Degranulation in LAD2 Cells**

All three known Orai isoforms are expressed in human lung MCs and participate in FcεRI-mediated activation (6). Moreover, in a
human MC line, LAD2 cells, shRNA-mediated silencing of STIM-1 results in significant decrease in MRGPRX2-mediated Ca\(^{2+}\) mobilization and degranulation (25). Given that STIM-1 couples to Orai1 for Ca\(^{2+}\) influx (26), we hypothesized that this CRAC channel contributes to SP-induced responses in human MCs. To test this possibility, we used lentiviral shRNA to individually silence the expression of Orai1, Orai2, and Orai3 in LAD2 cells, which endogenously express MRGPRX2. As shown in Figures 1A, B, transduction of LAD2 cells with lentiviral Orai1 resulted in >80% reduction of protein expression when compared to scrambled shRNA control, as determined by western blotting. This was associated with ~50% decrease in SP-induced Ca\(^{2+}\) influx (Figure 1C) and degranulation (Figure 1D). We found that although Orai2 silencing resulted in ~50% reduction in protein expression (Figures 1A, B), this was associated with significant inhibition of Ca\(^{2+}\) influx (Figure 1E) with small reduction in degranulation (Figure 1F). Knockdown of Orai3 in LAD2 cells resulted in ~50% decrease in protein expression (Figures 1A, B). This was associated with a small but significant reduction in SP-induced Ca\(^{2+}\) influx (Figure 1G) and degranulation (Figure 1H).

**SP-Induced Cytokine/Chemokine Production is Substantially Inhibited in Orai Knockdown LAD2 Cells**

In addition to degranulation, Orai-mediated Ca\(^{2+}\) influx regulates the activities of the transcription factors NFAT and NF-κB, which are required for cytokine/chemokine induction in immune cells (27, 28). We therefore sought to determine the effects Orai1, Orai2 or Orai3 knockdown on SP-induced TNF-α, IL-8, and CCL-3 generation in LAD2 cells. Despite the fact that individual Orai1 and Orai3 knockdown resulted in ~50% inhibition SP-induced Ca\(^{2+}\) influx and degranulation (Figure 1), this resulted in substantial inhibition of SP-induced cytokine/chemokine generation (Figures 2A–C). By contrast, knockdown of Orai2 had variable effects on SP-induced TNF-α, IL-8, and CCL-3 generation (Figures 2A–C).

**CRAC Channel Inhibitor Synta66 Inhibits SP-Induced Responses in LAD2 Cells**

Synta66 is a CRAC inhibitor that inhibits the formation of Orai1:Orai1, Orai1:Orai2, and Orai1:Orai3 dimers (29). Therefore, we used Synta66 to determine the combined role of Orai channels
on SP-induced Ca\(^{2+}\) influx, degranulation and cytokine/chemokine production. Pretreatment of LAD2 cells with Synta66 (10 \(\mu\)M) resulted in substantial reduction of SP-induced Ca\(^{2+}\) influx (Figure 3A) but complete inhibition of degranulation (Figure 3B), TNF-\(\alpha\), IL-8 and CCL-3 generation (Figures 3C–E). Involvement of extracellular signal-regulated kinases 1/2 (ERK1/2) and Akt pathways in cytokine production in MCs are well documented (30, 31). Furthermore, MRGPRX2-mediated MC activation leads to increased ERK1/2 and Akt phosphorylation (32, 33). STIM-1 inhibitor SKF pretreatment caused inhibition of ERK1/2 and Akt phosphorylation in LL-37 stimulated MCs via MRGPRX2 (25). We therefore sought to determine the effects of Synta66 on ERK1/2 and Akt phosphorylation in LAD2 cells. As shown in Figures 3F–H, SP stimulation resulted in time dependent enhanced ERK1/2 and Akt (Ser473) phosphorylation, which were significantly inhibited by Synta66.

Synta66 Inhibits SP-Induced Ca\(^{2+}\) Influx and Degranulation in Primary Human Skin MCs

In addition to LAD2 cells, SP causes degranulation in human skin MCs via MRGPRX2 (24, 34). To determine the biological relevance of studies with LAD2 cells, we tested the effect of Synta66 on SP-induced Ca\(^{2+}\) influx and degranulation in primary human skin-derived MCs isolated from three different donors. Initially, cell surface expression of MRGPRX2 in skin MCs was tested by flow cytometry. Representative flow cytometry traces for MRGPRX2 expression in skin MCs from three healthy donors are shown in Supplementary Figure 1. We found that SP triggered Ca\(^{2+}\) influx and degranulation in skin-derived MCs in all three donors (Figures 4A–F). Stimulation of human skin-derived MCs with SP resulted in Ca\(^{2+}\) mobilization from both intracellular stores as well as Ca\(^{2+}\) influx from the extracellular medium (Figures 4A, C, E). Synta66 (10 \(\mu\)M) specifically blocked Ca\(^{2+}\) influx with no effect on intracellular Ca\(^{2+}\) release (Figures 4A, C, E). Synta66 also caused significant inhibition in SP-induced degranulation in skin-derived MCs (Figures 4B, D, F).

Synta66 Attenuates SP-Induced Degranulation in Mouse PMCs In Vitro and Vascular Permeability and Peritonitis In Vivo

Our next goal was to determine the effect of Synta66 on MrgprB2-mediated responses in primary mouse PMCs in vitro and biological responses in vivo. First, we used PMCs from wild-type (WT) and MrgprB2\(^{-/-}\) mice to confirm that SP causes degranulation in PMCs via MrgprB2. As shown in Supplementary Figure 2, SP caused degranulation in WT-PMCs which is completely abrogated in MrgprB2\(^{-/-}\) PMCs. Furthermore, we found that Synta66 (10 \(\mu\)M) ablated SP-induced degranulation in mouse PMCs, as measured by both \(\beta\)-hexosaminidase release and cell surface expression of LAMP-1 by flow cytometry (Figures 5A, B). Gating strategy for LAMP-1 expression by flow cytometry was shown in Supplementary Figure 3. To determine the effect of blocking Orai channels on mouse cutaneous MCs degranulation in vivo, we administered Synta66 or vehicle intraperitoneally (i.p) followed by Evans blue dye injection through intravenous route. SP was then injected into one ear and vehicle into the other. The data presented in Figure 5C clearly demonstrate that, consistent with its effect on human skin MCs (Figure 4), Synta66 inhibited murine cutaneous MC degranulation in vivo as determined by a significant reduction in SP-induced Evans blue dye extravasation.

We also sought to determine if Synta66 inhibits cytokine production and the recruitment of inflammatory cells in vivo. Mice were injected (i.p) with Synta66 prior to intraperitoneal injection with SP or vehicle. Three hours later, serum TNF-\(\alpha\) concentration and neutrophil recruitment in peritoneal lavage (CD45\(^{+}\)CD11b\(^{+}\)Ly6G\(^{+}\) live cells) were quantitated. As shown in
Figure 5D, serum TNF-α level was significantly reduced in Synta66-treated mice. SP injection caused recruitment of inflammatory cells at peritoneal cavity and Synta66 substantially inhibited SP-induced leukocyte recruitment especially neutrophils (Figures 5E–G and Supplementary Figure 4).

DISCUSSION

Ca2+ is an indispensable second messenger signaling for agonist induced MC activation and mediator release (35). FcεRI and MRGPRX2-mediated signaling utilize both shared and distinct pathways that lead to Ca2+ mobilization and degranulation. Both FcεRI and MRGPRX2 mediated signaling caused comparable level of Ca2+ mobilization, however there is marked differences in spatiotemporal pattern of granule exocytosis and mediator content (16). Moreover, FcεRI stimulation cause PLCγ dependent Ca2+ influx while MRGPRX2 couples to Goαq to promote Ca2+ influx (35, 36). Identification of Ca2+ channel in FcεRI-mediated signaling is well characterized and Orai plays a crucial role in antigen-IgE-dependent MC activation (6–8, 37, 38). However, the possibility that MC activation via MRGPRX2/MrgprB2 requires Orai channels has not been determined. Using shRNA-mediated knockdown of Orai1/Orai2/Orai3 and a pharmacological inhibitor, we provide the first demonstration that Orai channels are involved in MRGPRX2/MrgprB2-mediated MC activation in vitro and vascular permeability and leukocytes recruitment in vivo.

Ashmole et al. demonstrated that transcripts of all three known Orai channels are expressed in human lung MCs. Moreover, Orai1 mRNA is most abundant isoform in human lung MCs (6). However, our data showed comparable expression of all three Orai proteins in LAD2 cells which suggests there might be variable level expression of Orai isoforms in different MC lineage. Knockdown of Orai1 resulted in inhibition of FcεRI-dependent Ca2+ influx and mediator release (7). Similarly, we found that Orai1 significantly contributes to MRGPRX2-mediated Ca2+ influx and mediator release in LAD2 cells. Tsvilovskyy et al., recently showed that absence of Orai2 in mouse PMCs results in enhanced FcεRI and MrgprB2-mediated
Ca\textsuperscript{2+} mobilization and degranulation when compared to control cells (38). Based on this finding, it was proposed that Orai2 serves as a negative regulator for MCs degranulation via two possible mechanisms. One involving the formation of a heterodimer with Orai1 and thus preventing its activation and the other resulting in the formation of Orai2-STIM-1 complex rendering insufficient STIM-1 available for Orai1 activation. However, shRNA-mediated downregulation of Orai2 in human lung MCs has marginal inhibitory effects on IgE-mediated Ca\textsuperscript{2+} mobilization and degranulation (7). Our data demonstrated that although Orai2 knockdown caused significant reduction in Ca\textsuperscript{2+} mobilization, it has minimum effect on degranulation. The reason for the difference is not clear but could reflect differences in the expression level of Orai1 and Orai2 in human and rodent MCs. Thus, while human lung MCs and LAD2 cells express Orai1 at >10-fold higher than that of Orai2, rodent MCs express both proteins at similar levels (8, 39). In addition, unlike Orai1, majority of the Orai2 is found in intracellular sites in rat basophilic leukemia (RBL-2H3) cells and the possibility that intracellular Orai2 could modulate Ca\textsuperscript{2+} influx has been suggested but the mechanism is not clear (39). Ashmole et al., successfully utilized adenoviral shRNA to silence the expression of Orai1 and Orai2 but not Orai3 in human lung MCs (7). However, our attempt to knockdown Orai3 in LAD2 cells using lentiviral shRNA was more successful and resulted in partial reduction in SP-induced Ca\textsuperscript{2+} influx and degranulation. Given that Orai1 and Orai3 are expressed at similar levels in human primary MCs and LAD2 cells, it is possible that Orai1:Orai3 dimer contributes to SP-induced signaling and mediator release (8). Because we were unable to silence the expression of Orai3 to >50% in LAD2 cells, it was not feasible to simultaneously reduce the expression both Orai1 and Orai3. Synta66 is an established pharmacological inhibitor that blocks homo- and heterodimer formation of Orai channel (29). Furthermore, Synta66 causes substantial inhibition of IgE-mediated degranulation in human lung MCs and LAD2 cells and blocks allergen-induced bronchial smooth muscle contraction \textit{ex vivo} (6, 7). However, because Orai2 is expressed at low level in MCs and found predominantly in the cytoplasm, any inhibitory effect of Synta66 likely reflects its ability to target Orai1 and Orai3 (8, 39). Here, we also found that Synta66 caused complete inhibition of SP-induced Ca\textsuperscript{2+} influx and degranulation, indicating probable involvement of Orai1:Orai3 dimer in MRGPRX2-mediated MC activation. Along with cultured MCs, Synta66 exhibited similar inhibitory effect on primary human skin-derived MCs indicating its biological relevance.

Calcium influx initiates a cascade of downstream signaling that lead to calmodulin–calcineurin dependent NFAT1 and NF-κB activation resulted in transcription of cytokine genes (40, 41). Calcium-dependent NFAT activation caused IL-17 and TNF-α secretion associated with autoimmune disease rheumatoid arthritis (42). Orai1 also modulates Th1 and Th17 responses in experimental autoimmune encephalomyelitis (43). Moreover, Orai also contributes FcεRI-mediated release of an array of inflammatory cytokines such as TNF-α, IL-5, IL-6, IL-8, and IL-13 from human lung MCs (8). The data presented herein...
demonstrate that knockdown of individual Orai channel significantly reduce proinflammatory cytokine/chemokine secretion. Blocking of Orai channel using pharmacological inhibitor showed complete ablation of cytokine/chemokine generation which may be due to its inhibitory effect on multiple Orai isoforms. In agreement with the cytokine production Synta66 pretreatment caused inhibition of ERK1/2 and Akt phosphorylation.

As for human MCs, rodent MCs also express all three Orai family members (44). Orai1 plays a predominant role in Ca\(^{2+}\) signaling in murine T-cells \textit{in vitro} and \textit{in vivo}. Nonfunctional Orai1 knock-in mice showed impaired Ca\(^{2+}\) influx \textit{in vitro} and reduced delayed hypersensitivity and colitis \textit{in vivo} (45). Although mutation in Orai1 in human patient has no major phenotypic effect, Orai\(^{-/-}\) mice cannot survive (46–48). Therefore, use of pharmacological inhibitor for Orai could overcome the lethality associated with genetic deletion of Orai1 \textit{in vivo}. Our data on isolated peritoneal MCs demonstrated complete inhibition of SP-induced degranulation by Synta66. MC degranulation is associated with enhanced vascular permeability and cutaneous anaphylaxis. Synta66 pretreatment inhibited SP-induced vascular permeability (early MC response) and reduced immune cell recruitment and cytokine production (delayed MC response).

In conclusion, we have utilized gene-silencing and pharmacological strategies to show that multiple Orai/CRAC channels contribute to SP-induced MRGPRX2-mediated Ca\(^{2+}\) influx, degranulation, TNF-\(\alpha\), IL-8 and CCL-3 generation in MCs \textit{in vitro}. Most importantly, we found that SP-induced increased vascular permeability and neutrophil recruitment, which are mediated via MrgrpB2, are blocked by Synta66. These findings suggest that Orai channel inhibitors could serve as a novel strategy for the modulation of neurogenic inflammation, pain, chronic urticaria, mastocytosis and atopic dermatitis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Internal Review Board at the University of South...
and analysis. We also thank Drs. Arnold Kirshenbaum and Dean Metcalfe (NIAID/NIH) for providing a human MC line LAD2 cells.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.803335/full#supplementary-material

Supplementary Figure 1 | Cell Surface Expression of MRGPRX2 in Human Skin MCs from Three Donors. Skin MCs were incubated with PE-conjugated anti-MRGPRX2 antibody (blue histograms) or isotype control antibody (grey histograms) and receptor expression was assessed by flow cytometry N=3.

Supplementary Figure 2 | SP Induces Degranulation in Mouse PMCs via MrgprB2. Peritoneal MCs from WT and MrgprB2−/− mice were exposed to SP and β2-hexosaminidase release was determined. Data presented are mean ± SEM of N=3 experiments. Statistical significance was determined by two-way ANOVA with Tukey’s multiple comparisons at a value ***p < 0.001.

Supplementary Figure 3 | Flow Cytometry Gating Strategy of LAMP1 Expression in PMCs N=3.

Supplementary Figure 4 | Flow cytometry gating strategy of peritoneal lavage immune cells. Numbers indicate the percentage of cells pre-gated on viability. Debris-cells, single cells, CD45+ live cells, CD45+CD11b+Ly6G+ live cells immune cells. Numbers indicate the percentage of cells pre-gated on viability. Debris-cells, single cells, CD45+ live cells, CD45+CD11b+Ly6G+ live cells (neutrophils).

REFERENCES

1. Galli SJ, Gaudenzio N, Tsai M. Mast Cells in Inflammation and Disease: Recent Progress and Ongoing Concerns. Annu Rev Immunol (2020) 38:49–77. doi: 10.1146/annurev-immunol-071719-094903

2. Shaw PJ, Feske S. Physiological and Pathophysiological Functions of SOCE in the Immune System. Front Biosci (2012) 4:2253–68. doi: 10.2741/c540

3. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orai1 Is an Essential Pore Subunit of the CRAC Channel. Nature (2006) 443(7108):230–3. doi: 10.1038/nature05122

4. Derler I, Jardin I, Romanin C. Molecular Mechanisms of STIM/Orai Communication. Am J Physiol Cell Physiol (2016) 310(8):C643–62. doi: 10.1152/ajpcell.00007.2016

5. Vig M, DeHaven WL, Bird GS, Billingsley JM, Wang H, Rao PE, et al. Defective Mast Cell Effector Functions in Mice Lacking the CRACM1 Pore Subunit of Store-Operated Calcium Release-Activated Calcium Channels. Nat Immunol (2008) 9:89–96. doi: 10.1038/ni1550

6. Ashmole I, Duffy SM, Leyland ML, Morrison VS, Begg M, Bradding P. CRACM/Orai Ion Channel Expression and Function in Human Lung Mast Cells. J Allergy Clin Immunol (2012) 129:1628–35.e2. doi: 10.1016/j.jaci.2012.01.070

7. Ashmole I, Duffy SM, Leyland ML, Bradding P. The Contribution of Orai (CRACM1) and Orai(CRACM2) Channels in Store-Operated Ca2+ Entry and Mediator Release in Human Lung Mast Cells. PLoS One (2013) 8:e74895. doi: 10.1371/journal.pone.0074895

8. Wajdner HE, Farrington J, Barnard C, Peachell PT, Schnackenberg CG, Marino JP Jr, et al. Orai and TRPC Channel Characterization in FcεRI-Mediated Calcium Signaling and Mediator Secretion in Human Mast Cells. Physiol Rep (2017) 5(3):e13166. doi: 10.14814/phy2.13166

9. Roy S, Chalatip CAN, Thapaliya M, Deepak V, Ali H. Multifaceted MRGPRX2: New Insight Into the Role of Mast Cells in Health and Disease. J Allergy Clin Immunol (2021) 148(2):293–308. doi: 10.1016/j.jaci.2021.03.049

10. Amponnawarat A, Chalatip CAN, Ali H, Murepavadin, A Small Molecule Host Defense Peptide Mimetic, Activates Mast Cells via MRGPRX2 and Mrgprb2. Front Immunol (2021) 12:689410. doi: 10.3389/fimmu.2021.689410

11. Van der Does AM, Bergman P, Agerberth B, Lindbom L. Induction of the Human Cathelicidin LL-37 as a Novel Treatment Against Bacterial Infections. J Leukoc Biol (2012) 92(4):735–42. doi: 10.1189/jlb.0412178

12. Brzezinska-Blaszczyk E, Zaleswska A. In Vitro Reactivity of Mast Cells in Urticaria Pigmentosa Skin. Arch Dermatol Res (1998) 290:14–7. doi: 10.1007/s004030050270

13. Deepak V, Komarow HD, Alblaisess AA, Carter MC, Metcalfe DD, Ali H. Expression of MRGPRX2 in Skin Mast Cells of Patients With Maculopapular Cutaneous Mastocytosis. J Allergy Clin Immunol Pract (2021) 9(10):3841–3.e1. doi: 10.1016/j.jaip.2021.05.042

14. Serhan N, Basso L, Sibilano R, Petitfils C, Meixiong J, Bonnart C, et al. House Dust Mites Activate Nociceptor-Mast Cell Clusters to Drive Type 2 Skin Inflammation. Nat Immunol (2019) 20:1435–43. doi: 10.1038/s41590-019-0493-z

15. Green DP, Limjuyosawong N, Gour N, Pandir D, Dong X. A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain. Neuron (2019) 101:412–20.e3. doi: 10.1016/j.neuron.2019.01.012

16. Gaudenzio N, Sibilano R, Marichal T, Starkl P, Reber LL, Cenac N, et al. Different Activation Signals Induce Distinct Mast Cell Degranulation Strategies. J Clin Invest (2016) 126:3981–98. doi: 10.1172/JCI85538

17. Alkanfari I, Freeman KB, Roy S, Jahan T, Scott RW, Ali H. Small-Molecule Host-Defense Peptide Mimetic Antibacterial and Antifungal Agents Activate Human and Mouse Mast Cells via Mas-Related GPCRs. Cells (2019) 8:311. doi: 10.3390/cells8040311

18. Chalatip CAN, Amponnawarat A, Roy S, Carol AO, Ali H. MRGPRX2 Activation by Rocuronium: Insight From Studies With Human Skin Mast Cells and Missense Variants. Cells (2021) 10:156. doi: 10.3390/cells10010156

19. Kambe N, Kambe M, Kochan JP, Schwartz LB. Human Skin-Derived Mast Cells can Proliferate While Retaining Their Characteristic Functional and
Protease Phenotypes. *Blood* (2001) 97(7):2045–52. doi: 10.1182/blood.V97.7.2045
20. Roy S, Gupta K, Ganguly A, Ali H. β-Arrestin2 Expressed in Mast Cells Regulates Ciprofloxacin-Induced Pseudooallergy and IgE-Mediated Anaphylaxis. *J Allergy Clin Immunol* (2019) 162(4):603–6. doi: 10.1016/j.jaci.2019.04.024
21. Roy S, Ganguly A, Haque M, Ali H. Angiogenic Host Defense Peptide AG-30/5C and Bradynadin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells. *J Immunol* (2019) 202:1229–38. doi: 10.4049/jimmunol.1801227
22. Chalatip CAN, Roy S, Alkanfari I, Ganguly A, Ali H. Identification of Gain and Loss of Function Missense Variants in MRGPRX2’s Transmembrane and Intracellular Domains for Mast Cell Activation by Substance P. *J Mol Sci* (2019) 20:5247. doi: 10.3390/jms20215247
23. Luissant AC, Williams HC, Kim W, Flemming S, Axectia V, Hilgarth RS, et al. Macrophage-Dependent Neutrophil Recruitment Is Impaired Under Conditions of Increased Ingestible Permeability in JAM-Deficient Mice. *Mucosal Immunol* (2019) 12:668–78. doi: 10.1038/s41385-019-0143-7
24. Fujisawa D, Kashiwakura I, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto M, et al. Orai-MRGPRX2/B2 Interaction in Mast Cells. *Biochem Biophys Res Commun* (2014) 451:62–7. doi: 10.1016/j.jbc.2014.07.060
25. Occhiuto CJ, Kammala AK, Yang C, Nellutla R, Garcia M, Gomez G, et al. Orai Channel C-Terminal Peptides Are Key Modulators of STIM-Orai Coupling and Calcium Signal Generation. *Cell Calcium* (2018) 74:131–43. doi: 10.1016/j.ceca.2018.07.003
26. Baraniak JHH Jr., Zhou Y, Nwokonko RM, Jennette MR, Kazzaz SA, Stenson JM, et al. Orai1 (CRACM1) Is the Platelet SOC Channel and Essential for Store-Operated Ca 2+ Entry Through ORAI1 Is Critical for T Cell-Mediated Anaphylaxis. *J Immunol* (2016) 196:573. doi: 10.4049/jimmunol.1501406
27. Roy S, Gupta K, Ganguly A, Ali H. Regulation of FceRI Signaling in Mast Cells by G Protein-Coupled Receptor Kinase 2 MrgX Receptors. *J Allergy Clin Immunol* (2012) 80:1038–44. doi: 10.1016/j.jaci.2012.04.013
28. Xie G, Wang F, Peng X, Liang Y, Yang H, Li L. Mast Cell Toll-28. Yoast RE, Emrich SM, Zhang X, Xin P, Johnson MT, Fike AJ, et al. The Native Store-Operated Calcium Entry and NFAT Activation in Lymphocytes. *Cell Calcium* (2018) 78:56–65. doi: 10.1016/j.ceca.2017.11.003
29. Solis-Lopez A, Kriebes U, Marx A, Mannehbach S, Liedtke WB, Caterina MJ, et al. Analysis of TRPV Channel Activation by Stimulation of FceRI and MRGPR Receptors in Mouse Peritoneal Mast Cells. *PloS One* (2017) 12(2): e0171366. doi: 10.1371/journal.pone.0171366
30. Tsvilovskyy V, Solis-Lopez A, Schumacher D, Medert R, Roers A, Kriebes U, et al. Deletion of Orai2 Augments Endogenous CRAC Currents and Degranulation in Mast Cells Leading to Enhanced Anaphylaxis. *J Calcium* (2018) 71:24–33. doi: 10.1016/j.jca.2017.11.004
31. Ikeya M, Yamanoue K, Mochizuki Y, Komishi H, Tadokoro S, Tanaka M, et al. Orai-2 Is Localized on Secretory Granules and Regulates Antigen-Evoked Ca 2+ Mobilization and Exocytosis in Mast Cells. *Biochem Biophys Res Commun* (2014) 415:62–7. doi: 10.1016/j.jbc.2014.07.060
32. Dolmetsch RE, Lewis RS, Goodnow CC, Healy J. Differential Activation of Transcription Factors Induced by Ca2+ Response Amplitude and Duration. *Nature* (1997) 386(6627):855–8. doi: 10.1038/386855a0
33. Gwack Y, Fekes S, Sirkansen, Hrogan PG, Rao A. Signalling to Transcription: Store-Operated Ca2+ Entry and NFAT Activation in Lymphocytes. *Cell Calcium* (2007) 42:145–56. doi: 10.1016/j.ceca.2007.03.007
34. Miskin JE, Abrams CC, Goatley LC, Dixon LK. A Viral Mechanism for Inhibition of the Cellular Phosphatase Calcineurin. *Science* (1998) 281:562–5. doi: 10.1126/science.281.5376.562
35. Kaufmann U, Shaw PJ, Kozlaya H, Subramanian R, Gaida K, Unutmaz D, et al. Selective ORAI1 Inhibition Ameliorates Autoimmune Central Nervous System Inflammation by Suppressing Effector But Not Regulatory T Cell Function. *J Immunol* (2016) 196:573–85. doi: 10.4049/jimmunol.1501406
36. Clemens RA, Lowell CA. CRAC Channel Regulation of Innate Immune Cells in Health and Disease. *Cell Calcium* (2019) 78:56–65. doi: 10.1016/j.ceca.2019.01.003
37. McCarthy CA, Khalil S, Ma J, Oh-hora M, Yamashita M, Roether J, et al. Store-Operated Ca2+ Entry Through ORAI1 Is Critical for T Cell-Mediated Autoimmunity and Allograft Rejection. *J Immunol* (2010) 185(10):584–58. doi: 10.4049/jimmunol.1001796
38. Feske S. ORAI1 and STIM1 Deficiency in Human and Mouse: Roles of Storeoperated Ca2+ Entry in the Immune System and Beyond. *Immuno Rev* (2009) 231:189–209. doi: 10.1111/j.1600-065X.2009.00818.x
39. Braun A, Varga-Szabo D, Kleinschnitz C, Pleines I, Bender M, Austinat M, et al. Orai1 (CRACM1) Is the Platelet SOC Channel and Essential for Pathological Thrombus Formation. *Blood* (2009) 113:2056–63. doi: 10.1182/blood-2008-07-171611
40. Bergmeier W, Oh-Hora M, McCarr CA, Roden RC, Bray PF, Feske S. R39W Mutation in Orai1 Causes Impaired Calcium Influx in Platelets. *Blood* (2009) 113:675–8. doi: 10.1182/blood-2008-08-174516

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chaki, Alkanfari, Roy, Amponnawarat, Hui, Oskeritzian and Ali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is not guaranteed or permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.